Study on the Effects of Exogenous Testosterone on Threat Perception and Behavioral Avoidance
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01408498|
Recruitment Status : Completed
First Posted : August 3, 2011
Last Update Posted : October 16, 2012
|Condition or disease||Intervention/treatment||Phase|
|Testosterone's Effects on Threat Perception/Response||Drug: Testosterone||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||120 participants|
|Intervention Model:||Parallel Assignment|
|Primary Purpose:||Basic Science|
|Official Title:||Study on the Effects of Exogenous Testosterone on Threat Perception and Behavioral Avoidance|
|Study Start Date :||January 2012|
|Actual Primary Completion Date :||April 2012|
|Actual Study Completion Date :||April 2012|
No Intervention: Placebo Control
Control group who will not receive exogenous testosterone administration. Will act as a comparison group to the testosterone group.
Experimental: Testosterone administration group
Experimental group that will receive a single 10 g dose of 1% testosterone topical gel.
Topical administration of testosterone gel. Participants receive a one-time, single dose of 10 g of 1% testosterone gel.
Other Name: AngroGel
- Behavioral response [ Time Frame: 16 hours post testosterone administration ]Participants will be asked to give a public speech, but will be given the opportunity to postpone the speech to a future date. Postponement is considered an avoidance-oriented behavioral response to a perceived social threat.
- Physiological response [ Time Frame: 16 hours post testosterone administration ]Participants will have cortisol and cardiovascular tone tracked during the social threat protocol. Prior to, during, and after being asked, preparing, and giving a public speech, participants' physiological stress markers will be assessed.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01408498
|United States, Texas|
|Austin, Texas, United States, 78712|
|Principal Investigator:||Scott H Liening, B.A.||University of Texas at Austin|